$1.32
2.33% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$1.29
-0.14 9.79% 1M
-3.44 72.73% 6M
+0.02 1.57% YTD
-5.79 81.78% 1Y
-17.44 93.11% 3Y
-27.08 95.45% 5Y
-16.91 92.91% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.02 1.57%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $106.49m
Enterprise Value $-120.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.63
EV/Sales (TTM) EV/Sales -1.94
P/S ratio (TTM) P/S ratio 1.72
P/B ratio (TTM) P/B ratio 0.61
Revenue growth (TTM) Revenue growth 150.95%
Revenue (TTM) Revenue $61.76m
EBIT (operating result TTM) EBIT $-228.52m
Free Cash Flow (TTM) Free Cash Flow $-191.36m
Cash position $265.09m
EPS (TTM) EPS $-2.56
P/E forward negative
P/S forward 3.10
EV/Sales forward negative
Short interest 29.38%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Editas Medicine, Inc. forecast:

5x Buy
31%
9x Hold
56%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
31%
Hold
56%
Sell
13%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62 62
151% 151%
100%
- Direct Costs 5.89 5.89
5% 5%
10%
56 56
203% 203%
90%
- Selling and Administrative Expenses 64 64
4% 4%
104%
- Research and Development Expense 214 214
39% 39%
347%
-223 -223
10% 10%
-360%
- Depreciation and Amortization 5.89 5.89
5% 5%
10%
EBIT (Operating Income) EBIT -229 -229
10% 10%
-370%
Net Profit -211 -211
8% 8%
-341%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Neutral
Seeking Alpha
19 days ago
Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vi...
Neutral
Seeking Alpha
21 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Linda Burkly - Executive Vice President and Chief Scientific Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Brian Cheng Good m...
Neutral
GlobeNewsWire
23 days ago
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of concept data in non-human primates editing hematopoietic stem cells (HSCs) and li...
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 265
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today